Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

rVSV S GP/VP40

Next Previous
X
Search
Drug Profile

rVSV S GP/VP40

Alternative Names: BPSC-1001; Ebola vaccine - Merck & Co; Ebola virus vaccine - Lumos Pharma; ERVEBO; Public Health Agency of Canada's Ebola vaccine; rVSV delta G ZEBOV GP; rVSV-EBOV; rVSV-S-GP/VP40; rVSV-ZEBOV; rVSV-ZEBOV-GP; rVSVΔG-ZEBOV-GP; V-920; V920 Ebola Zaire Vaccine; VSV delta G ZEBOV; VSV delta-ZEBOV; VSV-EBOV; VSV-ZEBOV; VSVG-ZEBOV

Latest Information Update: 26 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Public Health Agency of Canada
  • Developer Canadian Immunization Research Network; Dalhousie University; Merck & Co; National Institute of Allergy and Infectious Diseases
  • Class Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Ebola virus infections

Most Recent Events

  • 06 Aug 2024 Merck Sharp & Dohme in collaboration with Emory University initiates a phase II trial for Ebola virus infections (Prevention) in USA (IM, Injection) (NCT06100913)
  • 20 Dec 2023 National Institute of Allergy and Infectious Diseases completes a phase II trial in Ebola virus infections (In infants, In children, In adolescents, In adults, In the elderly, Prevention) in Guinea, Liberia, Sierra Leone, Mali (IM) (NCT02876328)
  • 20 Oct 2023 Merck Sharp & Dohme in collaboration with Emory University plans a phase II trial for Ebola virus infections in USA (IM, Injection) (NCT06100913)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top